- ISIN
- US71715X2036
- CUSIP
- 71715X203
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 17, 2010
Highlights
- Market Cap
- $3.91M
- Enterprise Value
- -$18.60T
- EPS (TTM)
- -$0.41
- EBITDA (TTM)
- -$12.90M
- Year Range
- $0.55 - $1.51
- ROA (TTM)
- -0.00%
- ROE (TTM)
- -0.00%
- Avg. Volume (1M)
- 122K
- Avg. Volume Value (1M)
- $76.91K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PMCB Performance Chart
PharmaCyte Biotech, Inc. (PMCB) is down 20.4% since the beginning of the year. At $1 per share, PMCB is trading 61.9% below its 52-week high of $2. Investors who bought $1,000 worth of PMCB shares 5 years ago would now be looking at an investment worth $48.
Loading charts...
Compare this symbol against anything
Returns By Period
PharmaCyte Biotech, Inc. (PMCB) has returned -20.44% so far this year and -42.40% over the past 12 months. Over the last ten years, PMCB has returned -38.63% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
PharmaCyte Biotech, Inc.
- 1D
- -4.00%
- 1M
- -19.44%
- 6M
- -29.67%
- YTD
- -20.44%
- 1Y
- -42.40%
- 3Y*
- -40.02%
- 5Y*
- -45.53%
- 10Y*
- -38.63%
- ALL TIME*
- -16.58%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
PMCB Monthly Returns History
Based on dividend-adjusted daily data since Sep 17, 2010, PMCB's average daily return is +0.24%, while the average monthly return is +2.65%. At this rate, an investment would double in approximately 2.2 years.
Historically, 39% of months were positive and 61% were negative. The best month was Jan 2021 with a return of +168.7%, while the worst month was Aug 2021 at -71.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 10 months.
On a daily basis, PMCB closed higher 39% of trading days. The best single day was Aug 18, 2021 with a return of +189.5%, while the worst single day was Aug 19, 2021 at -64.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 13.12% | -15.74% | -3.58% | 8.51% | 15.57% | -7.72% | -25.19% | -20.44% | |||||
| 2025 | 2.22% | 9.91% | -29.14% | -0.80% | -17.31% | 6.30% | -6.42% | -7.94% | 3.26% | -4.08% | -16.82% | -6.41% | -53.89% |
| 2024 | 1.39% | -4.11% | 12.86% | -10.55% | -7.55% | 0.00% | -0.00% | -21.94% | 24.84% | -5.24% | -5.52% | -8.19% | -27.31% |
| 2023 | -1.37% | 3.81% | -3.00% | 0.34% | 7.88% | -9.21% | -6.99% | -7.89% | -14.29% | 0.95% | 6.60% | -4.42% | -26.28% |
| 2022 | -14.40% | -0.47% | 7.98% | 1.30% | -1.29% | -2.61% | 6.70% | 10.04% | -8.75% | 22.50% | 2.72% | -2.98% | 17.20% |
| 2021 | 168.66% | 53.89% | -38.27% | 3.60% | -28.31% | -14.96% | -28.26% | -71.94% | -5.93% | -11.04% | -8.16% | -3.47% | -75.93% |
Benchmark Metrics
PharmaCyte Biotech, Inc. has an annualized alpha of 75.41%, beta of 0.26, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 17, 2010.
- This stock participated in 152.74% of S&P 500 Index downside but only 19.38% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.26 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 75.41%
- Beta
- 0.26
- R²
- 0.00
- Upside Capture
- 19.38%
- Downside Capture
- 152.74%
Return for Risk
Risk / Return Rank
PMCB ranks 20 for risk / return — above 20% of stocks peers on PortfoliosLab. Its historical combined result is below the peer median.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for PharmaCyte Biotech, Inc. (PMCB) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PMCB | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.85 | ||
| Sortino ratioReturn per unit of downside risk | -2.18 | ||
| Omega ratioGain probability vs. loss probability | 0.98 | 1.25 | -0.28 |
| Calmar ratioReturn relative to maximum drawdown | -0.83 | 2.00 | -2.83 |
| Martin ratioReturn relative to average drawdown | -1.32 | 8.49 | -9.82 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the PharmaCyte Biotech, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the PharmaCyte Biotech, Inc. was 99.93%, occurring on Jul 31, 2026. The portfolio has not yet recovered.
The current PharmaCyte Biotech, Inc. drawdown is 99.93%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.93%Jul 2026 | 12y 5mo | — | 12y 5moFeb 2014 - now | — |
-66.67%Dec 2010 | 1mo 13d | 1mo 16d | 2mo 29dNov 2010 - Jan 2011 | — |
-66.20%Dec 2012 | 8mo 7d | 2mo 29d | 11mo 6dApr 2012 - Mar 2013 | — |
-61.43%Feb 2012 | 8mo 25d | 2mo 1d | 10mo 26dJun 2011 - Apr 2012 | — |
-53.75%Apr 2011 | 2mo 5d | 29d | 3mo 4dFeb 2011 - May 2011 | — |
Drawdown Indicators
| PMCB | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.93% | -56.78% | -43.15% |
Max Drawdown (1Y)Largest decline over 1 year | -52.79% | -9.10% | -43.69% |
Max Drawdown (3Y)Largest decline over 3 years | -77.93% | -18.90% | -59.03% |
Max Drawdown (5Y)Largest decline over 5 years | -94.21% | -25.43% | -68.78% |
Max Drawdown (10Y)Largest decline over 10 years | -99.76% | -33.92% | -65.84% |
Current DrawdownCurrent decline from peak | -99.93% | -1.58% | -98.35% |
Average DrawdownAverage peak-to-trough decline | -77.24% | -10.70% | -66.54% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 32.92% | 2.14% | +30.78% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of PharmaCyte Biotech, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how PharmaCyte Biotech, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PMCB
Add PharmaCyte Biotech, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PMCB